Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amphastar Pharmaceuticals, Inc. - Common Stock
(NQ:
AMPH
)
24.57
+0.01 (+0.04%)
Streaming Delayed Price
Updated: 10:30 AM EDT, Jun 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amphastar Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – An Undervalued Stock Worth Considering
June 12, 2025
AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) is an undervalued stock with strong profitability, reasonable financial health, and an attractive valuation, making it a candidate for value investors.
Via
Chartmill
3 Russell 2000 Stocks with Questionable Fundamentals
June 11, 2025
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...
Via
StockStory
3 Small-Cap Stocks Walking a Fine Line
May 29, 2025
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...
Via
StockStory
Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know
May 27, 2025
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports,...
Via
StockStory
Topics
Artificial Intelligence
Government
Stocks
Exposures
Artificial Intelligence
Political
Tariff
Earnings Scheduled For May 7, 2025
May 07, 2025
Via
Benzinga
Earnings Outlook For Amphastar Pharma
May 06, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
February 27, 2025
Via
Benzinga
Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers
May 22, 2025
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – A Potentially Undervalued Stock Worth Watching
May 17, 2025
AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) offers strong profitability and an undervalued stock price, making it a candidate for value investors. Check the full analysis for details.
Via
Chartmill
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
May 12, 2025
Via
Benzinga
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 Sales Targets
May 07, 2025
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $170.5 million. Its non-GAAP profit of $0.74...
Via
StockStory
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential
May 01, 2025
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential
Via
Chartmill
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of
April 29, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...
Via
StockStory
Topics
Stocks
Exposures
COVID-19
US Equities
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
April 28, 2025
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is an undervalued gem with solid fundamentals.
April 25, 2025
Uncover the potential of AMPHASTAR PHARMACEUTICALS IN, an undervalued stock. NASDAQ:AMPH maintains a strong financial position and offers an appealing valuation.
Via
Chartmill
2 Safe-and-Steady Stocks with Solid Fundamentals and 1 to Think Twice About
April 24, 2025
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Via
StockStory
Exposures
Ethanol
2 Reasons to Like AMPH and 1 to Stay Skeptical
April 15, 2025
What a brutal six months it’s been for Amphastar Pharmaceuticals. The stock has dropped 50.3% and now trades at $24.50, rattling many shareholders. This was partly due to its softer quarterly results...
Via
StockStory
Topics
Supply Chain
Exposures
Supply Chain
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), an undervalued stock with good fundamentals.
March 27, 2025
Take a closer look at AMPHASTAR PHARMACEUTICALS IN , a remarkable value stock. NASDAQ:AMPH excels in fundamentals and maintains a very reasonable valuation.
Via
Chartmill
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
March 13, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
March 05, 2025
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds
February 28, 2025
Amphastar's Q4 sales grew 20% to $186.5M, missing estimates. Primatene MIST surpassed $100M in annual sales, while Baqsimi saw strong growth.
Via
Benzinga
Amphastar: Earnings Miss, Margins Drop
February 28, 2025
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1%
February 27, 2025
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.7% year on year to $186.5 million. Its non-GAAP profit of $0.92 per...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow
February 26, 2025
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.
Via
StockStory
Top 2 Health Care Stocks That May Rocket Higher This Month
February 21, 2025
Via
Benzinga
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
February 21, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
February 19, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
NASDAQ:AMPH is an undervalued gem with solid fundamentals.
February 18, 2025
AMPHASTAR PHARMACEUTICALS IN is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:AMPH showcases decent financial health and profitability, coupled with an attractive price.
Via
Chartmill
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks
February 14, 2025
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group
February 13, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.